U.S. markets close in 5 hours 17 minutes
  • S&P 500

    4,044.25
    -32.32 (-0.79%)
     
  • Dow 30

    34,206.11
    -188.90 (-0.55%)
     
  • Nasdaq

    11,482.45
    +14.45 (+0.13%)
     
  • Russell 2000

    1,875.18
    -6.50 (-0.35%)
     
  • Crude Oil

    81.50
    +0.28 (+0.34%)
     
  • Gold

    1,795.20
    -20.00 (-1.10%)
     
  • Silver

    22.82
    -0.03 (-0.11%)
     
  • EUR/USD

    1.0470
    -0.0058 (-0.55%)
     
  • 10-Yr Bond

    3.6030
    +0.0740 (+2.10%)
     
  • GBP/USD

    1.2211
    -0.0045 (-0.37%)
     
  • USD/JPY

    135.3700
    +0.0640 (+0.05%)
     
  • BTC-USD

    16,951.11
    -19.72 (-0.12%)
     
  • CMC Crypto 200

    402.39
    +0.97 (+0.24%)
     
  • FTSE 100

    7,561.11
    +2.62 (+0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

NGM Bio Presents Preliminary Data From NGM120 Combo Trial In Pancreatic Cancer

  • NGM Biopharmaceuticals Inc (NASDAQ: NGMannounced updated preliminary findings from its Phase 1b dose escalation trial of NGM120 in metastatic pancreatic cancer.

  • The data were shared at the American Association for Cancer Research (AACR) Special Conference.

  • NGM120 has been well tolerated in patients in the Phase 1b combination cohort (NGM120 + gemcitabine + Nab-paclitaxel) with no dose-limiting toxicities.

  • Among the six evaluable patients in the Phase 1b combination cohort, a disease control rate of 100% was observed, median progression-free survival had not been reached, and the 12-month survival rate was 83.3%.

  • Three of the six evaluable patients experienced partial responses (PR) extending more than 32 weeks as of the abstract cut-off date, including one patient with a PR that was ongoing at 90 weeks as of August 15.

  • "Historic median progression-free survival in this patient population is approximately 5-7 months. While a small sample size, seeing two patients in this cohort exhibit partial response beyond 17 months is intriguing," said the abstract's first author.

  • NGM Bio is conducting a Phase 2 trial of NGM120 in combination with gemcitabine and Nab-paclitaxel as a first-line treatment in patients with metastatic pancreatic cancer, a Phase 1a trial testing NGM120 as monotherapy for solid tumors, and a recently initiated Phase 1b trial testing NGM120 in combination with one or more lines of hormone therapies in patients with metastatic castration-resistant prostate cancer (mCRPC).

  • Price Action: NGM shares closed lower by 6.32% at $15.13 on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.